Clinical Trials Arena June 14, 2024
GlobalData

The mRNA-1283 vaccine demonstrated higher efficacy in adults aged 18 years and above.

Moderna has announced that its Phase III clinical trial of the investigational next-generation Covid-19 vaccine, mRNA-1283, met its primary efficacy endpoint.

The vaccine demonstrated non-inferior efficacy against Covid-19 compared to Spikevax (mRNA-1273).

Notably, the trial observed higher efficacy in adults aged 18 years and above, with a consistent trend reported in those aged 65 years and older.

The observer-blind, randomised, active-controlled study involved approximately 11,400 participants aged 12 and above.

Participants were administered either a 10μg dose of mRNA-1283 or a 50μg dose of Spikevax.

In March this year, the company reported positive interim immunogenicity data from the vaccine trial.

The latest efficacy data align with the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID, Trends
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
Ozempic Shortages Raise Questions About Prioritizing Access For Diabetics
Weight Loss Pills Intensify Obesity Drug Race—But Here’s Why Experts Say Injections Aren’t Going Anywhere
Podcast: New Alzheimer's Drug Approval Expands Treatment Options – and Creates Coverage Questions
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs

Share This Article